Cargando…
Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials
Demonstrating a slowing in the rate of cognitive decline is a common outcome measure in clinical trials in Alzheimer’s disease (AD). Selection of cognitive endpoints typically includes modeling candidate outcome measures in the many, richly phenotyped observational cohort studies available. An impor...
Autores principales: | Aschenbrenner, Andrew J., Hassenstab, Jason, Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Salloway, Stephen, Farlow, Martin, Yaari, Roy, Cheng, Eden Y. J., Holdridge, Karen C., Mummery, Catherine J., Masters, Colin L., Hsiung, Ging-Yuek, Surti, Ghulam, Day, Gregory S., Weintraub, Sandra, Honig, Lawrence S., Galvin, James E., Ringman, John M., Brooks, William S., Fox, Nick C., Snyder, Peter J., Suzuki, Kazushi, Shimada, Hiroyuki, Gräber, Susanne, Bateman, Randall J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244171/ https://www.ncbi.nlm.nih.gov/pubmed/35783127 http://dx.doi.org/10.3389/fnagi.2022.883131 |
Ejemplares similares
-
Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019) -
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018) -
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022) -
Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022) -
Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2020)